Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy

Tibor Szarvas, Markus Becker, Frank Vom Dorp, Jan Meschede, André Scherag, Ágnes Bánkfalvi, Henning Reis, Kurt W. Schmid, I. Romics, Herbert Rübben, Süleyman Ergün

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Elevated matrix metalloproteinase-7 (MMP-7) tissue expression and serum concentration have been shown to be associated with cancer progression and metastasis. The aim of our study was to assess the prognostic value of preoperative circulating MMP-7 levels in serum samples of patients with clinically localized prostate cancer. Furthermore, we compared the serum MMP-7 levels between patients with organ confined and metastatic prostate cancer. MMP-7 levels were measured in 93 patients with localized prostate cancer, 13 patients with distant bone metastasis and in sera of 19 controls using enzyme-linked immunosorbent assay. The results were compared to the clinical follow-up data. We did not find any significant difference in MMP-7 serum levels between patients and controls (p = 0.268). Circulating MMP-7 serum concentration was significantly elevated in patients with distant metastasis (p <0.001). For the detection of distant prostate cancer metastasis, using a cut-off value of 3.7 ng/ml, a specificity of 69% and a sensitivity of 92% were observed. Multivariate analysis identified high MMP-7 serum concentration as an independent risk factor for prostate cancer-related death both in a preoperative and a postoperative model (p = 0.003 and 0.018, respectively). Furthermore, the evaluation of predictive models revealed that addition of serum MMP-7 levels to the preoperatively available predictors improves prognostic accuracy (the concordance index increased from 0.631 to 0.734 when MMP-7 was included). Based on these, we concluded that MMP-7 is a potential marker to identify patients with metastatic prostate cancer. In clinically localized prostate cancer, MMP-7 may provide independent prognostic information, thereby helping to optimize therapy decisions.

Original languageEnglish
Pages (from-to)1486-1492
Number of pages7
JournalInternational Journal of Cancer
Volume128
Issue number6
DOIs
Publication statusPublished - Mar 15 2011

Fingerprint

Matrix Metalloproteinase 7
Prostatectomy
Prostatic Neoplasms
Serum
Neoplasm Metastasis

Keywords

  • matrilysin
  • metastasis
  • MMP-7
  • prognosis
  • prostate cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Szarvas, T., Becker, M., Vom Dorp, F., Meschede, J., Scherag, A., Bánkfalvi, Á., ... Ergün, S. (2011). Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy. International Journal of Cancer, 128(6), 1486-1492. https://doi.org/10.1002/ijc.25454

Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy. / Szarvas, Tibor; Becker, Markus; Vom Dorp, Frank; Meschede, Jan; Scherag, André; Bánkfalvi, Ágnes; Reis, Henning; Schmid, Kurt W.; Romics, I.; Rübben, Herbert; Ergün, Süleyman.

In: International Journal of Cancer, Vol. 128, No. 6, 15.03.2011, p. 1486-1492.

Research output: Contribution to journalArticle

Szarvas, T, Becker, M, Vom Dorp, F, Meschede, J, Scherag, A, Bánkfalvi, Á, Reis, H, Schmid, KW, Romics, I, Rübben, H & Ergün, S 2011, 'Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy', International Journal of Cancer, vol. 128, no. 6, pp. 1486-1492. https://doi.org/10.1002/ijc.25454
Szarvas T, Becker M, Vom Dorp F, Meschede J, Scherag A, Bánkfalvi Á et al. Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy. International Journal of Cancer. 2011 Mar 15;128(6):1486-1492. https://doi.org/10.1002/ijc.25454
Szarvas, Tibor ; Becker, Markus ; Vom Dorp, Frank ; Meschede, Jan ; Scherag, André ; Bánkfalvi, Ágnes ; Reis, Henning ; Schmid, Kurt W. ; Romics, I. ; Rübben, Herbert ; Ergün, Süleyman. / Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy. In: International Journal of Cancer. 2011 ; Vol. 128, No. 6. pp. 1486-1492.
@article{a3e905aaff304608be393212992ab24e,
title = "Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy",
abstract = "Elevated matrix metalloproteinase-7 (MMP-7) tissue expression and serum concentration have been shown to be associated with cancer progression and metastasis. The aim of our study was to assess the prognostic value of preoperative circulating MMP-7 levels in serum samples of patients with clinically localized prostate cancer. Furthermore, we compared the serum MMP-7 levels between patients with organ confined and metastatic prostate cancer. MMP-7 levels were measured in 93 patients with localized prostate cancer, 13 patients with distant bone metastasis and in sera of 19 controls using enzyme-linked immunosorbent assay. The results were compared to the clinical follow-up data. We did not find any significant difference in MMP-7 serum levels between patients and controls (p = 0.268). Circulating MMP-7 serum concentration was significantly elevated in patients with distant metastasis (p <0.001). For the detection of distant prostate cancer metastasis, using a cut-off value of 3.7 ng/ml, a specificity of 69{\%} and a sensitivity of 92{\%} were observed. Multivariate analysis identified high MMP-7 serum concentration as an independent risk factor for prostate cancer-related death both in a preoperative and a postoperative model (p = 0.003 and 0.018, respectively). Furthermore, the evaluation of predictive models revealed that addition of serum MMP-7 levels to the preoperatively available predictors improves prognostic accuracy (the concordance index increased from 0.631 to 0.734 when MMP-7 was included). Based on these, we concluded that MMP-7 is a potential marker to identify patients with metastatic prostate cancer. In clinically localized prostate cancer, MMP-7 may provide independent prognostic information, thereby helping to optimize therapy decisions.",
keywords = "matrilysin, metastasis, MMP-7, prognosis, prostate cancer",
author = "Tibor Szarvas and Markus Becker and {Vom Dorp}, Frank and Jan Meschede and Andr{\'e} Scherag and {\'A}gnes B{\'a}nkfalvi and Henning Reis and Schmid, {Kurt W.} and I. Romics and Herbert R{\"u}bben and S{\"u}leyman Erg{\"u}n",
year = "2011",
month = "3",
day = "15",
doi = "10.1002/ijc.25454",
language = "English",
volume = "128",
pages = "1486--1492",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy

AU - Szarvas, Tibor

AU - Becker, Markus

AU - Vom Dorp, Frank

AU - Meschede, Jan

AU - Scherag, André

AU - Bánkfalvi, Ágnes

AU - Reis, Henning

AU - Schmid, Kurt W.

AU - Romics, I.

AU - Rübben, Herbert

AU - Ergün, Süleyman

PY - 2011/3/15

Y1 - 2011/3/15

N2 - Elevated matrix metalloproteinase-7 (MMP-7) tissue expression and serum concentration have been shown to be associated with cancer progression and metastasis. The aim of our study was to assess the prognostic value of preoperative circulating MMP-7 levels in serum samples of patients with clinically localized prostate cancer. Furthermore, we compared the serum MMP-7 levels between patients with organ confined and metastatic prostate cancer. MMP-7 levels were measured in 93 patients with localized prostate cancer, 13 patients with distant bone metastasis and in sera of 19 controls using enzyme-linked immunosorbent assay. The results were compared to the clinical follow-up data. We did not find any significant difference in MMP-7 serum levels between patients and controls (p = 0.268). Circulating MMP-7 serum concentration was significantly elevated in patients with distant metastasis (p <0.001). For the detection of distant prostate cancer metastasis, using a cut-off value of 3.7 ng/ml, a specificity of 69% and a sensitivity of 92% were observed. Multivariate analysis identified high MMP-7 serum concentration as an independent risk factor for prostate cancer-related death both in a preoperative and a postoperative model (p = 0.003 and 0.018, respectively). Furthermore, the evaluation of predictive models revealed that addition of serum MMP-7 levels to the preoperatively available predictors improves prognostic accuracy (the concordance index increased from 0.631 to 0.734 when MMP-7 was included). Based on these, we concluded that MMP-7 is a potential marker to identify patients with metastatic prostate cancer. In clinically localized prostate cancer, MMP-7 may provide independent prognostic information, thereby helping to optimize therapy decisions.

AB - Elevated matrix metalloproteinase-7 (MMP-7) tissue expression and serum concentration have been shown to be associated with cancer progression and metastasis. The aim of our study was to assess the prognostic value of preoperative circulating MMP-7 levels in serum samples of patients with clinically localized prostate cancer. Furthermore, we compared the serum MMP-7 levels between patients with organ confined and metastatic prostate cancer. MMP-7 levels were measured in 93 patients with localized prostate cancer, 13 patients with distant bone metastasis and in sera of 19 controls using enzyme-linked immunosorbent assay. The results were compared to the clinical follow-up data. We did not find any significant difference in MMP-7 serum levels between patients and controls (p = 0.268). Circulating MMP-7 serum concentration was significantly elevated in patients with distant metastasis (p <0.001). For the detection of distant prostate cancer metastasis, using a cut-off value of 3.7 ng/ml, a specificity of 69% and a sensitivity of 92% were observed. Multivariate analysis identified high MMP-7 serum concentration as an independent risk factor for prostate cancer-related death both in a preoperative and a postoperative model (p = 0.003 and 0.018, respectively). Furthermore, the evaluation of predictive models revealed that addition of serum MMP-7 levels to the preoperatively available predictors improves prognostic accuracy (the concordance index increased from 0.631 to 0.734 when MMP-7 was included). Based on these, we concluded that MMP-7 is a potential marker to identify patients with metastatic prostate cancer. In clinically localized prostate cancer, MMP-7 may provide independent prognostic information, thereby helping to optimize therapy decisions.

KW - matrilysin

KW - metastasis

KW - MMP-7

KW - prognosis

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=79551469486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551469486&partnerID=8YFLogxK

U2 - 10.1002/ijc.25454

DO - 10.1002/ijc.25454

M3 - Article

VL - 128

SP - 1486

EP - 1492

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 6

ER -